Poorly Differentiated Thyroid Carcinoma: Diagnostic Features and Controversial Issues
Tóm tắt
Poorly differentiated thyroid carcinomas are a heterogeneous group of tumors occupying an area intermediate between well-differentiated follicular or papillary carcinoma and anaplastic carcinomas, from both a histopathogenetic and a clinical point of view. Large tumor series selected on the basis of structural and/or other morphological criteria showed that poorly differentiated carcinomas have a distinct biological behavior, and the classification of these tumors into a separate group appears justified, although strict homogeneous diagnostic criteria should be achieved and widely accepted to better characterize such tumor entity. Moreover, the identification of the prognostic parameters segregating aggressive from indolent cases has important clinical implications. Molecular data in the literature, although limited by the heterogeneous case series analyzed, identify ras alterations as the most common molecular alteration in poorly differentiated carcinomas, thus, depicting a peculiar molecular pathway in this tumor type as compared to well-differentiated follicular and papillary carcinomas. The present paper aims to review the various aspects of this tumor type, from morphology to immunohistochemistry and molecular abnormalities from a practical and daily practice-oriented point of view.
Tài liệu tham khảo
Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849–55, 1983 doi:10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X.
Cabanne F, Gerard-Marchant R, Heimann R, Williams ED. Tumeurs malignes du corps thyroide. Problèmes de diagnostic histopathologique. A propos de 692 lèsions recuilles par le groupe coopèrateur de l’O.E.R.T.C. Ann Anat Pathol 19:129–48, 1974.
Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (“insular”) thyroid carcinoma. Am J Surg Pathol 8:655–68, 1984 doi:10.1097/00000478-198409000-00005.
Pilotti S, Collini P, Mariani L, et al. Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol 21:1466–73, 1997 doi:10.1097/00000478-199712000-00009.
Sobrinho-Simoes M, Sambade C, Fonseca E, Soares P. Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol 10:123–31, 2002 doi:10.1177/106689690201000205.
Nishida T, Katayama S, Tsujimoto M, Nakamura J, Matsuda H. Clinicopathological significance of poorly differentiated thyroid carcinoma. Am J Surg Pathol 23:205–11, 1999 doi:10.1097/00000478-199902000-00010.
Ljungberg O, Bondeson L, Bondeson AG. Differentiated thyroid carcinoma, intermediate type: a new tumor entity with features of follicular and parafollicular cell carcinoma. Hum Pathol 15:218–28, 1984 doi:10.1016/S0046-8177(84)80183-5.
Papotti M, Botto Micca F, Favero A, Palestini N, Bussolati G. Poorly differentiated thyroid carcinomas with primordial cell component. A group of aggressive lesions sharing insular, trabecular, and solid patterns. Am J Surg Pathol 17:291–301, 1993 doi:10.1097/00000478-199303000-00010.
Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, Mayer M, Sylvester RJ, van Glabbeke M. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 15:1033–41, 1979 doi:10.1016/0014-2964(79)90291-3.
Ashfaq R, Vuitch F, Delgado R, Albores-Saavedra J. Papillary and follicular thyroid carcinomas with an insular component. Cancer 73:416–23, 1994 doi:10.1002/1097-0142(19940115)73:2<416::AID-CNCR2820730229>3.0.CO;2-O.
Sobrinho-Simões M. Poorly differentiated thyroid carcinomas. Endocr Pathol 7:99–102, 1996 doi:10.1007/BF02739969.
Akslen LA, LiVolsi VA. Poorly differentiated thyroid carcinoma–it is important. Am J Surg Pathol 24:310–3, 2000 doi:10.1097/00000478-200002000-00030.
Nishiyama RH. Another dissertation on poorly differentiated carcinomas: is it really necessary? Adv Anat Pathol 6:281–6, 1999.
Pilotti S, Collini P, Manzari A, Marubini E, Rilke F. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin Diagn Pathol 12:249–55, 1995.
DeLellis RA, LLoyd R, Heitz PU. WHO classification of tumors, pathology and genetics—tumors of endocrine organs. Lyon: IARC, 2004.
Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Path 31:1256–64, 2007 doi:10.1097/PAS.0b013e3180309e6a.
Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 25:1478–84, 2001doi:10.1097/00000478-200112000-00002.
Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular and solid patterns. A clinico-pathological study of 183 cases. Cancer 100:950–7, 2004 doi:10.1002/cncr.20087.
Hiltzik D, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106:1286–95, 2006 doi:10.1002/cncr.21739.
Sasaki A, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S. Insular component as a risk factor of thyroid carcinoma. Pathol Int 46:939–46, 1996.
Rufini V, Salvatori M, Fadda G, et al. Thyroid carcinomas with a variable insular component: prognostic significance of histopathologic patterns. Cancer 110:1209–17, 2007 doi:10.1002/cncr.22913.
Papotti M, Torchio B, Grassi L, Favero A, Bussolati G. Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol 20:686–94, 1996 doi:10.1097/00000478-199606000-00005.
Seoane JM, Cameselle-Teijeiro J, Romero MA. Poorly differentiated oxyphilic (Hürthle cell) carcinoma arising in lingual thyroid: a case report and review of the literature. Endocr Pathol 13:353–60, 2002 doi:10.1385/EP:13:4:353.
Decaussin M, Bernard MH, Adeleine P, et al. Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol 26:1007–15, 2002 doi:10.1097/00000478-200208000-00005.
Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88:1902–8, 2000 doi:10.1002/(SICI)1097-0142(20000415)88:8<1902::AID-CNCR20>3.0.CO;2-Y.
Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113(1):48–56, 2008 doi:10.1002/cncr.23515.
Lin JD, Chao TC, Hsueh C. Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas. Clin Endocrinol (Oxf) 66:224–8, 2007doi:10.1111/j.1365-2265.2006.02712.x.
Jung TS, Kim TY, Kim KW, et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J 54:265–74, 2007 doi:10.1507/endocrj.K06-166.
Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. World J Surg 31:934–45, 2007 doi:10.1007/s00268-007-9033-3.
Pulcrano M, Boukheris H, Talbot M, et al. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid 17:639–46, 2007 doi:10.1089/thy.2007.0029.
Tallini G, Garcia-Rostan G, Herrero A, et al. Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 23:678–85, 1999 doi:10.1097/00000478-199906000-00007.
Dobashi Y, Sugimura H, Sakamoto A, et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 3:9–14, 1994.
Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753–60, 1993 doi:10.1172/JCI116385.
Basolo F, Pisaturo F, Pollina LE, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19–23, 2000.
Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226–35, 2003 doi:10.1200/JCO.2003.10.130.
Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simões M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42:580–7, 2003 doi:10.1046/j.1365-2559.2003.01642.x.
Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987–96, 2001.
Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–404, 2003 doi:10.1210/jc.2003-030838.
Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 444:572–6, 2004 doi:10.1007/s00428-004-1018-0.
Santoro M, Papotti M, Chiappetta G, et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370–9, 2002 doi:10.1210/jc.87.1.370.